Johnson & Johnson (NYSE: JNJ) is deliberately stepping back from the GLP-1 weight-loss drug market, a sector widely valued at over $100 billion.
CEO Joaquin Duato has made clear he has no intention of chasing the weight-loss drug trend, preferring instead to focus on oncology and the company’s sprawling medical device business.
The decision stands in sharp contrast to the strategy of Eli Lilly (NYSE: LLY), which has leaned heavily into GLP-1 drugs and become a Wall Street favorite as a result.
That reliance on a single category, however, carries its own risks, with weight-loss drugs now accounting for nearly two-thirds of Eli Lilly’s total revenues.
Novo Nordisk is also a major player in the GLP-1 space, and several other pharmaceutical companies are racing to develop competing drugs in the same category.
The market enthusiasm around GLP-1 drugs has been so intense that many investors now treat a company’s participation in the sector as a prerequisite for serious consideration.
Duato is pushing back against that logic, arguing that Johnson & Johnson’s diversified approach across multiple healthcare segments gives the company a more resilient foundation.
The valuation gap between the two companies is a significant factor for investors weighing their options in the pharmaceutical space.
Eli Lilly’s price-to-earnings ratio currently sits above 40x, while Johnson & Johnson trades at a comparatively modest 29x earnings, reflecting its lower-profile but steadier business model.
Johnson & Johnson also offers a dividend yield of 2.1%, a meaningfully more attractive income proposition than Eli Lilly’s yield of just 0.6%.
For investors focused on long-term stability rather than near-term momentum, Johnson & Johnson’s deliberate avoidance of the GLP-1 race may ultimately prove to be a disciplined and rewarding strategic choice.
The company’s ability to grow without exposure to the volatile weight-loss drug category could make it a more dependable compounder for patient, income-oriented investors over time.
